CN1190581A - 复方利福平注射液 - Google Patents
复方利福平注射液 Download PDFInfo
- Publication number
- CN1190581A CN1190581A CN98113445A CN98113445A CN1190581A CN 1190581 A CN1190581 A CN 1190581A CN 98113445 A CN98113445 A CN 98113445A CN 98113445 A CN98113445 A CN 98113445A CN 1190581 A CN1190581 A CN 1190581A
- Authority
- CN
- China
- Prior art keywords
- injection
- effect
- isoniazid
- pyrazinamide
- tuberculosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种用于治疗结核病的注射药物,其成分为:1000ml该药物内含利福平30~70g、异烟肼25~60g、吡嗪酰胺40~80g、丙二醇300~600ml、磷酸盐缓冲液余量。本发明具有吸收完全、作用迅速、疗效确切的特点,并且可治疗全身各器官、各种类型的结核病,用途广泛,尤其对难治、复治病例疗效显著。此外,本发明减少了毒、副作用,避免了肝脏的首过效应和胃肠道副作用,并且减少了过敏反应。
Description
本发明涉及一种用于治疗结核病的注射药物。
利福平、异烟肼、吡嗪酰胺是常用的抗结核药物。利福平(Rifampicin)为广谱高效抗菌药,特别对结核杆菌有高度的抗菌活性,难溶于水,易溶于甲醇、醋酸乙酯。临床应用中发现,细菌对利福平极易产生耐药性,口服利福平对人体毒副作用较多,特别是对肝脏和消化道的作用。异烟肼(Isoniazid)具有特异性的抗结核杆菌作用,毒性小,但结核杆菌对该药易产生抗药性,长期服用易引起肝损害,该药对神经系统也有副作用。吡嗪酰胺(Pyrazinamide)对细胞内的结核杆菌有杀灭作用,其副作用较多,并与剂量大小有关。上述三种药中异烟肼有注射剂,利福平、吡嗪酰胺只有口服制剂,口服药无法避免其对肝脏和消化道的毒副作用,并且没有复合药物,其功效单一。
本发明的目的是提供一种主要成份为利福平、异烟肼和吡嗪酰胺的抗结核注射剂,以提高疗效,延缓细菌产生耐药性,减少药物对肝脏和消化道的毒副作用。
本发明的方案是:一种治疗结核病的复方注射剂,其成份为:1000ml注射剂内含利福平30~70g、异烟肼25~60g、吡嗪酰胺40~80g、丙二醇300~600ml、磷酸盐缓冲液余量。
上述磷酸盐缓冲液的成份为:每1000ml内含磷酸二氢钠1.8~4.2g、磷酸氢二钠3.8~8.6g、水余量。
本发明成功地将利福平、异烟肼和吡嗪酰胺组合成一种全新抗结核病注射剂药物,解决了利福平难溶于水及溶解后的稳定性问题,延缓了细菌产生耐药性。本发明具有吸收完全、作用迅速、疗效确切的特点,并且可治疗全身各器官、各种类型的结核病,用途广泛,尤其对难治、复治病例疗效显著。此外,本发明减少了毒、副作用,避免了肝脏的首过效应和胃肠道副作用,并且减少了过敏反应。
上述磷酸盐缓冲液为:将磷酸二氢钠1.8~4.2g、磷酸氢二钠3.8~8.6g溶于注射用水1000ml中配制而成,该缓冲液的PH值应为6.0~7.5。
本发明的制备方法为:
1、将所需的磷酸盐缓冲液分成A、B两部分;
2、将异烟肼和吡嗪酰胺加入磷酸盐缓冲液A中,加热使其完全溶解,称为甲液;
3、将利福平加入丙二醇中,搅拌使其溶解,称为乙液;
4、将甲液加入到乙液中,并兑加磷酸盐缓冲液B;
5、加入活性炭,加热煮沸后放至室温;
6、过滤、灌装、消毒灭菌。
Claims (2)
1、一种用于治疗结核病的注射药物,其特征在于成份为:1000ml该药物内含利福平30~70g、异烟肼25~60g、吡嗪酰胺40~80g、丙二醇300~600ml、磷酸盐缓冲液余量。
2、按权利要求1所述的注射药物,其特征在于磷酸盐缓冲液为:1000ml该缓冲液含磷酸二氢钠1.8~4.2g、磷酸氢二钠3.8~8.6g、水余量。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN98113445A CN1190581A (zh) | 1998-02-25 | 1998-02-25 | 复方利福平注射液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN98113445A CN1190581A (zh) | 1998-02-25 | 1998-02-25 | 复方利福平注射液 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1190581A true CN1190581A (zh) | 1998-08-19 |
Family
ID=5223170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN98113445A Pending CN1190581A (zh) | 1998-02-25 | 1998-02-25 | 复方利福平注射液 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1190581A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000057187A2 (en) * | 1999-03-19 | 2000-09-28 | Vanderbilt University | Diagnosis and treatment of multiple sclerosis |
US6258532B1 (en) | 1997-08-14 | 2001-07-10 | Vanderbilt University | Methods for in vitro susceptibility testing of chlamydia |
US6710033B1 (en) | 1996-08-14 | 2004-03-23 | Vanderbilt University | Methods and treatment of multiple sclerosis |
US6890526B2 (en) | 1997-05-06 | 2005-05-10 | Vanderbilt University | Methods and reagents for the treatment of multiple sclerosis |
CN100348193C (zh) * | 2005-10-09 | 2007-11-14 | 沈阳双鼎制药有限公司 | 一种利福平药物及其制备方法 |
CN1989966B (zh) * | 2005-12-30 | 2011-06-08 | 重庆华邦制药股份有限公司 | 含利福平和异烟肼的药物组合物 |
-
1998
- 1998-02-25 CN CN98113445A patent/CN1190581A/zh active Pending
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6710033B1 (en) | 1996-08-14 | 2004-03-23 | Vanderbilt University | Methods and treatment of multiple sclerosis |
US6890526B2 (en) | 1997-05-06 | 2005-05-10 | Vanderbilt University | Methods and reagents for the treatment of multiple sclerosis |
US6258532B1 (en) | 1997-08-14 | 2001-07-10 | Vanderbilt University | Methods for in vitro susceptibility testing of chlamydia |
US7094397B2 (en) | 1997-08-14 | 2006-08-22 | Vanderbilt Unversity | Methods and reagents for the treatment of multiple sclerosis |
WO2000057187A2 (en) * | 1999-03-19 | 2000-09-28 | Vanderbilt University | Diagnosis and treatment of multiple sclerosis |
WO2000057187A3 (en) * | 1999-03-19 | 2001-04-19 | Univ Vanderbilt | Diagnosis and treatment of multiple sclerosis |
CN100348193C (zh) * | 2005-10-09 | 2007-11-14 | 沈阳双鼎制药有限公司 | 一种利福平药物及其制备方法 |
CN1989966B (zh) * | 2005-12-30 | 2011-06-08 | 重庆华邦制药股份有限公司 | 含利福平和异烟肼的药物组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1288346C (en) | Use of n-acetylglucosamine for the therapy of degenerative joint disease and related diseases | |
WO2001085137A3 (en) | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use | |
AP2001002288A0 (en) | Methods for treatment of sickle cell anemia. | |
JP2002524415A5 (zh) | ||
TR200103153T2 (tr) | Yeni bileşimler | |
US11896598B2 (en) | Appetite suppressant compositions and methods thereof | |
WO2001060412A3 (en) | Modification of biopolymers for improved drug delivery | |
JPS63145229A (ja) | ビタミンb6含有医薬組成物 | |
CN1190581A (zh) | 复方利福平注射液 | |
FR2497669A1 (fr) | Preparation pharmaceutique ayant d'excellentes proprietes d'absorption | |
JPS58131962A (ja) | 新規アミノ酸誘導体の製法 | |
WO2005065429B1 (en) | Composition and method for treatment of hepatic encephalopathy | |
EP1108429A3 (en) | An improved amino acid composition for providing an amino acid supplement or protein substitute, particularly for the treatment and/or management of certain diseases | |
CA3074541C (en) | Appetite suppressant compositions and methods thereof | |
CN111840512B (zh) | 治疗软骨修复和/或骨关节炎的组合物 | |
CN100377712C (zh) | 葫芦素脂质体组方及其制剂 | |
KR960015953B1 (ko) | 피부에 축적하는 외용의 항바이러스성 약학적 조성물 및 그 제조방법 | |
JP3096052B2 (ja) | 脂質代謝調節剤 | |
CA2408920A1 (en) | Methods for prevention of ulcers and improving physiological performance | |
JP2004500315A5 (zh) | ||
CN102391499B (zh) | 一种还原刺激下快速释放乳香酸活性成分的聚合物的制备方法 | |
JPS632926A (ja) | 安定な、注射可能な制吐性組成物 | |
CN101690714A (zh) | 一种用于抗微生物、原虫和肿瘤的大蒜素脂质体及其制备方法 | |
RU2088239C1 (ru) | Состав, проникающий через кожу, для лечения остеоартроза | |
CA2321265A1 (en) | Antibacterial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Gao Xuxia Document name: Approval notice for cost mitigation |
|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |